减少内内注射相关内炎的发生率,使用预装注射器
Henry L Feng1, Shareif Abdelwahab2, Nareena Imam2
1Illinois Retina Associates, Department of Ophthalmology, Rush University Medical Center, Chicago, IL, USA.
Journal of vitreoretinal diseases
|November 6, 2023
概括
与未预填充的选项相比,用于抗VEGF药物的预填充注射器显著降低了内炎风险. 这一发现凸显了无菌制剂在预防注射后感染方面的重要性.
科学领域:
- 眼科医生 眼科 眼科
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 对抗VEGF药物的静脉内注射是治疗视网膜疾病的常见方法.
- 视内膜炎是内内注射后的一种严重并发症.
- 反VEGF药物的制备方法可能会影响感染风险.
研究的目的:
- 为了比较预填注射器和非预填注射器中的抗VEGF药物之间的内炎发病率.
- 分析注射相关内炎的临床特征和结果.
主要方法:
- 在2014年1月1日至2019年12月31日期间注射的静脉内抗VEGF注射的回顾性图表审查.
- 鉴定和分析被诊断为注射相关内炎的眼睛.
- 基于药物类型 (预填与非预填) 的内炎率和微生物发现的比较.
主要成果:
- 总共有325,990次注射被审查,其中88例是内炎的病例.
- 拉尼比祖马布预填注射器 (RANPFS) 的内炎发病率最低,为0.0154%,相比之下,贝瓦西祖马布 (0.0312%),拉尼比祖马布 (0.0226%) 和阿弗利伯塞普 (0.0366%).
- RANPFS显示了显著较低的培养证明内眼炎率 (P = .003),视力敏度结果在各组中相似.
结论:
- 预装注射器中的抗VEGF药物可能会降低在制备过程中药物污染的风险.
- 与未预填充的抗VEGF药物相比,Ranibizumab预填充注射器 (RANPFS) 与注射相关的内炎的发病率较低.
- 预填注射器代表了一种潜在的更安全的选择,用于静脉内抗VEGF的管理.
相关概念视频
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...


